{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4,"youtube":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"DURGA-6","nct_id":"NCT07735637","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=durga-6-nct07735637. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"DURGA-6","arms":[{"description":"AZD0120 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy.","label":"Arm A: AZD0120","type":"EXPERIMENTAL"},{"description":"ASCT: High-dose melphalan followed by autologous stem cell rescue","label":"Arm B: Autologous Stem Cell Transplant (ASCT)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2039-11-09","type":"ESTIMATED"},"conditions":["Newly Diagnosed Multiple Myeloma (NDMM)"],"enrollment":{"count":750,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"AZD0120","type":"BIOLOGICAL"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Fludarabine","type":"DRUG"},{"name":"Melphalan (part of ASCT)","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"}],"last_update":"2026-07-30","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)","overall_status":"NOT_YET_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2028-10-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS)","timeFrame":"Up to approximately 13 years."},{"measure":"Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)","timeFrame":"Up to approximately 13 years."}],"references":[],"start_date":{"date":"2026-08-25","type":"ESTIMATED"},"study_type":"INTERVENTIONAL","title":"A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).","url":"https://clinicaltrials.gov/study/NCT07735637"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/durga-6-nct07735637"}